Andrew Komjathy serves as Chief Commercial Officer of the Company. Mr. Komjathy was the Vice President, Commercial Sales at Alkermes, Inc., a publicly held pharmaceutical company, from May 2014 to November 2018. From 2012 to 2014, he was the Vice President, Sales for the U.S. Multiple Sclerosis Business Unit at Genzyme, a publicly held pharmaceutical company. From 2005 to 2012, Mr. Komjathy held three Vice President positions at Shire Human Genetic Therapies, initially as Vice President and General Manager, Commercial Operations in the North American and Asia-Pacific regions, followed by Vice President, Global Franchise Leader for Fabry/Gaucher in Switzerland, and ultimately as Vice President, Commercial Operations. From 1996 to 2005, Mr. Komjathy held positions of increasing responsibility at Biogen. Mr. Komjathy holds an M.B.A. from New York University Stern School of Business and his B.S. in Business Administration from Bucknell University.
Andrew Komjathy is 57, he's been the Chief Commercial Officer of Astria Therapeutics Inc since 2019. There are 7 older and 3 younger executives at Astria Therapeutics Inc. The oldest executive at Astria Therapeutics Inc is Michael Kishbauch, 71, who is the Independent Director.
Andrew's mailing address filed with the SEC is C/O CATABASIS PHARMACEUTICALS, INC.,, 100 HIGH STREET, FLOOR 28, BOSTON, MA, 02110.
Over the last 9 years, insiders at Astria Therapeutics Inc have traded over 0$ worth of Astria Therapeutics Inc stock and bought 3,064,797 units worth 36,777,564$ . The most active insiders traders include Jean George、Nicholas Galakatos、Lifesciences Ii, L.P.Clarus.... On average, Astria Therapeutics Inc executives and independent directors trade stock every 0 days with the average trade being worth of 2,617,339$. The most recent stock trade was executed by Lifesciences Ii, L.P.Clarus... on 30 June 2015, trading 376,695 units of CATB stock currently worth 4,520,340$.
Astria Therapeutics Inc executives and other stock owners filed with the SEC include: